Methods for Increasing the Selective Efficacy of Gene Therapy Using CAR Peptide and Heparan Sulfate Mediated Macropinocytosis
AssigneeVascular Biosciences
InventorDavid Mann
Life of this patent
Estimating the term…
Abstract
Disclosed are compositions and methods for triggering disease selective macropinocytosis. The compositions can serve as a marker of disease activity and as a trigger of enhanced macropinocytosis in tissues undergoing disease remodeling such as wound healing, cancer, PAH, inflammation, diabetes, Crohn's disease, ulcerative colitis, ankylosing spondylitis, diseases of the endometrium, psoriasis, irritable bowel syndrome, arthritis, fibrotic disorders, interstitial cystitis, autoimmune diseases, asthma, acute lung injury, and adult respiratory distress syndrome. The compositions can also serve as a receptor for disease selective cell penetrating peptides in the cells and extracellular matrix of diseased tissues.
Claims13
A method for diagnosing the health status of an individual suffering from Pulmonary Arterial Hypertension (PAH), the method comprising:
- a) obtaining a sample from an individual suffering from PAH;
- b) measuring heparanase and heparan sulfate levels in the sample obtained in step a);
- c) determining the health status of the individual based on the heparanase and heparan sulfate levels obtained in step b.
A method for increasing the localized efficacy of gene therapy in an individual suffering from a disease by co-administering a therapeutically effective amount of a composition consisting of:
- 1) at least one cell-penetrating peptide;
- and
- 2) at least one other therapeutic agent,
- wherein at least one compound of the composition induces increased macropinocytosis of diseased cells.
Dependencies are inferred from the claim text.